<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021488</url>
  </required_header>
  <id_info>
    <org_study_id>2009-I053</org_study_id>
    <nct_id>NCT01021488</nct_id>
  </id_info>
  <brief_title>Rosuvastatin for Preventing Deep Vein Thrombosis</brief_title>
  <acronym>STOP-DVT</acronym>
  <official_title>Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep vein thrombosis (DVT)is devastating disease which influencing the mortality and
      morbidity of patients at-risk like those undergoing orthopedic surgery.

      Recent publication suggested HMO-co-A reductase inhibitor (statin) may reduce the occurrence
      rate of venous thromboembolism in apparently healthy persons.

      The pleiotropic property of statin like antioxidant, antithrombotic, anti-inflammatory may
      have effect on the positive results.

      We are investigating whether rosuvastatin is associated with lower incidence of deep vein
      thrombosis (DVT) in patients undergoing total knee replacement arthroplasty(TKRA)who are
      at-high risk for developing DVT
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of deep vein thrombosis diagnosed and confirmed by CT angiography at lower extremities</measure>
    <time_frame>7days after index surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-dimer, lipid panel (Total cholesterol, TG, HDL, LDL), hsCRP, CK, transaminase, ALP</measure>
    <time_frame>7days, 1month, 2month after index surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous</condition>
  <condition>Thrombosis</condition>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>Experimental: Rosuvastatin + enoxaparin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg/d for 14days</intervention_name>
    <description>Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.</description>
    <arm_group_label>Experimental: Rosuvastatin + enoxaparin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin only</intervention_name>
    <description>enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery</description>
    <arm_group_label>enoxaparin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are going to receive total knee replacement arthroplasty from any cause.

          -  &lt; 19 years old

        Exclusion Criteria:

          -  patients with cancer

          -  Patients receiving anticoagulant agents from any cause

          -  current statin users

          -  expecting survival from other co-morbidity &lt; 1year

          -  Bed ridden patient

          -  AST, ALT &gt; 3times of upper normal limit

          -  CK&gt; upper normal limit

          -  pregnancy

          -  patients who receives hormone replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Ho Jo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Ho Jo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Jin Choi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang-Ho Jo, MD</last_name>
    <phone>82-31-380-3722</phone>
    <email>sophi5@medimail.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital, Department of Cardiology and Orthopedic Surgery</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Ho Jo, MD</last_name>
      <phone>82-31-380-3722</phone>
      <email>sophi5@medimail.co.kr</email>
    </contact>
    <contact_backup>
      <last_name>mikyung Baek</last_name>
      <phone>82-31-380-1975</phone>
      <email>mikyungb@hallym.or.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2009</study_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hallym University Sacred Heart Hospital, Department of Internal Medicine, Division of Cardiology</name_title>
    <organization>Hallym University Sacred Heart Hospital</organization>
  </responsible_party>
  <keyword>Thrombosis</keyword>
  <keyword>Vein</keyword>
  <keyword>Statin</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

